Advertisement

Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review

  • Amelia J. HicksEmail author
  • Fiona J. Clay
  • Jennie L. Ponsford
  • Luke A. Perry
  • Mahesh Jayaram
  • Rachel Batty
  • Malcolm Hopwood
Review

Abstract

Pseudobulbar affect is a debilitating condition that significantly reduces quality of life for many individuals following traumatic brain injury (TBI). It is characterized by embarrassing and often uncontrollable episodes of crying or laughter. The aim of this systematic review was to evaluate the effectiveness of pharmacotherapy as compared to all other comparators for the management of pseudobulbar affect in adults who have sustained TBI. Six databases were searched, with additional hand searching of journals, clinical trials registries and international drug regulators to identify published and unpublished studies in English up to June 2018. Studies were eligible for this review if they included adults who had sustained a medically confirmed TBI and presented with pseudobulbar affect. All pharmacotherapy and comparator interventions were considered for inclusion, and study design was not limited to randomised controlled trials. Evidence quality was assessed using Joanna Briggs Institute Critical Appraisal Instruments. Two quasi-experimental studies examining the effectiveness of dextrometamorphan/quinidine (DM/Q) were identified. These studies reported that DM/Q was effective in reducing symptoms of pseudobulbar affect and had a positive safety profile, over follow-up periods of 3 months (n = 87) and 12 months (n = 23). However, both studies were limited by lack of a control group and a high dropout rate. The findings of twelve case reports examining the effectiveness of DM/Q (n = 6) and anti-depressants (n = 6) are also discussed. Further research is required to determine which pharmacological interventions provide the best outcomes for individuals with pseudobulbar affect following TBI, with consideration given to side effect profiles and financial costs.

Keywords

Pseudobulbar affect Traumatic brain injury TBI Pharmacotherapy Effectiveness 

Abbreviations

CT

computed tomography

CNS-LS

Center for Neurologic studies Emotional Lability Scale

DM/Q

dextrometamorphan/quinidine

Dur

duration

Freq

Frequency

GCS

Glasgow Coma Scale

HI

head injury

hrs

hours

JBI

Joanna Briggs Institute

MRI

magnetic resonance imaging

mths

months

NR

not reported

N/A

not applicable

PBA

pseudobulbar affect

PLCS

Pathological Laughter and Crying Scale

PRN

pro re nata (i.e. as needed)

PTA

post traumatic amnesia

RoB

Risk of Bias

SSRI

selective serotonin reuptake inhibitor

TBI

traumatic brain injury

TCA

tricyclic anti-depressant

wk.

weeks

yrs.

years

Notes

Acknowledgements

The authors acknowledge with thanks the input of our information specialist Farhad Shokraneh in the design of search strategies.

Funding Information

The project was funded by the Transport Accident Commission (TAC) through the Institute for Safety, Compensation and Recovery Research (ISCRR).The funder was not involved in any other aspect of the project. This includes study design, data collection, analysis and interpretation of data, writing of the report or decision to submit the article for publication.

Compliance with Ethical Standards

Conflict of Interest

One of the chief investigators (MH) has given talks on this topic for which travel and accommodation has been paid by the organizers. In addition, he has accepted fees for consulting and research from the pharmaceutical companies Bionomics, Eli Lilly, Janssen-Cilag, Lundbeck, Novartis, Pfizer, Praxisand Servier. Lundbeck. All other authors declare no known competing interests.

Supplementary material

11065_2020_9427_MOESM1_ESM.docx (43 kb)
ESM 1 (DOCX 42 kb)

References

  1. Adams, J. H., Doyle, D., Ford, I., Gennarelli, T., Graham, D., & McLellan, D. (1989). Diffuse axonal injury in head injury: Definition, diagnosis and grading. Histopathology, 15(1), 49–59.CrossRefGoogle Scholar
  2. Ahmed, A., & Simmons, Z. (2013). Pseudobulbar affect: prevalence and management. Therapeutics and Clinical Risk Management, 9, 483–489.  https://doi.org/10.2147/TCRM.S53906 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Allman, P., Hope, R. A., & Fairburn, C. G. (1990). Emotionalism following brain damage: A complex phenomenon. Postgraduate Medical Journal, 66(780), 818–821.CrossRefGoogle Scholar
  4. Anderson, I. M. (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of Affective Disorders, 58(1), 19–36.CrossRefGoogle Scholar
  5. Arciniegas, D. B., Lauterbach, E. C., Ginsberg, D. L., Anderson, K. E., Chow, T. W., Flashman, L. A., et al. (2014). The differential diagnosis of Pseudobulbar affect (PBA): Distinguishing PBA among disorders of mood and affect. CNS Spectrums, 10(S5), 1–16.  https://doi.org/10.1017/s1092852900026602 CrossRefGoogle Scholar
  6. Arciniegas, D. B., & Wortzel, H. S. (2014). Emotional and behavioral dyscontrol after traumatic brain injury. Psychiatric Clinics of North America, 37(1), 31–53.  https://doi.org/10.1016/j.psc.2013.12.001 CrossRefPubMedGoogle Scholar
  7. Atkinson, K. M., Koenka, A. C., Sanchez, C. E., Moshontz, H., & Cooper, H. (2015). Reporting standards for literature searches and report inclusion criteria: Making research syntheses more transparent and easy to replicate. Research Synthesis Methods, 6(1), 87–95.  https://doi.org/10.1002/jrsm.1127 CrossRefPubMedGoogle Scholar
  8. Beller, E. M., Glasziou, P. P., Altman, D. G., Hopewell, S., Bastian, H., Chalmers, I., … PRISMA for Abstracts Group. (2013). PRISMA for abstracts: Reporting systematic reviews in journal and conference abstracts. PLoS Medicine, 10(4), e1001419.  https://doi.org/10.1371/journal.pmed.1001419 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Beresford, T. P., Arciniegas, D., Clapp, L., Martin, B., & Alfers, J. (2005). Reduction of affective lability and alcohol use following traumatic brain injury: A clinical pilot study of anti-convulsant medications. Brain Injury, 19(4), 309–313.  https://doi.org/10.1080/02699050410001720121 CrossRefPubMedGoogle Scholar
  10. Brooks, B. R., Crumpacker, D., Fellus, J., Kantor, D., & Kaye, R. E. (2013). PRISM: A novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLoS One, 8(8), e72232.  https://doi.org/10.1371/journal.pone.0072232 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Brooks, B. R., Thisted, R. A., Appel, S. H., Bradley, W. G., Olney, R. K., Berg, J. E., … AVP-923 ALS Study Group. (2004). Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology, 63(8), 1364–1370.  https://doi.org/10.1212/01.WNL.0000142042.50528.2F CrossRefPubMedGoogle Scholar
  12. Chahine, L. M., & Chemali, Z. (2006). Du rire aux larmes: Pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. Epilepsy & Behavior, 8(3), 610–615.  https://doi.org/10.1016/j.yebeh.2006.01.017 CrossRefGoogle Scholar
  13. Chen, J. J. (2017). Pharmacotherapeutic management of pseudobulbar affect. American Journal of Managed Care, 23(18 Suppl), S345–S350.PubMedGoogle Scholar
  14. Clay, F., Hicks, A. J., Perry, L. J., Ponsford, J. L., Jayaram, M., & Hopwood, M. (2018). Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: A systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 9 In Press.Google Scholar
  15. Colamonico, J., Formella, A., & Bradley, W. (2012). Pseudobulbar affect: Burden of illness in the USA. Advances in Therapy, 29(9), 775–798.  https://doi.org/10.1007/s12325-012-0043-7 CrossRefPubMedGoogle Scholar
  16. Cruz, M. P. (2013). Nuedexta for the treatment of pseudobulbar affect: A condition of involuntary crying or laughing. P T, 38(6), 325–328.PubMedPubMedCentralGoogle Scholar
  17. Cummings, J. L., Arciniegas, D. B., Brooks, B. R., Herndon, R. M., Lauterbach, E. C., Pioro, E. P., et al. (2014). Defining and diagnosing involuntary emotional expression disorder. CNS Spectrums, 11(S6), 1–11.  https://doi.org/10.1017/s1092852900026614 CrossRefGoogle Scholar
  18. Cummings, J., Gilbart, J., & Andersen, G. (2013). Pseudobulbar affect. A disabling but under-recognized consequence of neurological disease and brain injury. European Neurological Review, 8(2), 74–81.CrossRefGoogle Scholar
  19. Duda, J. E. (2014). History and prevalence of involuntary emotional expression disorder. CNS Spectrums, 12(S5), 6–10.  https://doi.org/10.1017/s1092852900025955 CrossRefGoogle Scholar
  20. Fellus, J., DeFina, P., Carson, C., Machado, C., & Chinchilla, M. (2014). Dextromethorphan/quinidine alleviates pseudobulbar affect and rapidly eliminates suicidal ideation in individuals with traumatic brain injury. Functional Neurology, Rehabilitation, and Ergonomics, 4(4), 253.Google Scholar
  21. Fonda, J. R., Hunt, P. R., McGlinchey, R. E., Rudolph, J. L., Milberg, W. P., Reynolds, M. W., et al. (2015). Identification of pseudobulbar affect symptoms in veterans with possible traumatic brain injury. Journal of Rehabilitation Research and Development, 52(7), 839–849.  https://doi.org/10.1682/JRRD.2014.08.0191 CrossRefPubMedGoogle Scholar
  22. Garcia-Baran, D., Johnson, T. M., Wagner, J., Shen, J., & Geers, M. (2016). Therapeutic approach of a high functioning individual with traumatic brain injury and subsequent emotional volatility with features of pathological laughter and crying with dextromethorphan/quinidine. Medicine (Baltimore), 95(12), e2886.  https://doi.org/10.1097/MD.0000000000002886 CrossRefGoogle Scholar
  23. Gennarelli, T. A., Thibault, L. E., & Graham, D. I. (1998). Diffuse axonal injury: An important form of traumatic brain damage. The Neuroscientist, 4(3), 202–215.CrossRefGoogle Scholar
  24. Hammond, F. M., Alexander, D. N., Cutler, A. J., D’Amico, S., Doody, R. S., Sauve, W., et al. (2016). PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology, 16(1), 89.CrossRefGoogle Scholar
  25. Hammond, F. M., Sauve, W., Ledon, F., Davis, C., & Formella, A. E. (2018). Safety, tolerability, and effectiveness of dextromethorphan/quinidine for Pseudobulbar affect among study participants with traumatic brain injury: Results from the PRISM-II open label study. PM&R.Google Scholar
  26. Johnston, S. C., & Hauser, S. L. (2007). Marketing and drug costs: Who is laughing and crying? Annals of Neurology, 61(2), 11A–12A.  https://doi.org/10.1002/ana.21100 CrossRefPubMedGoogle Scholar
  27. Lawson, I. R., & MacLoed, R. D. (1969). The use of imipramine (" Tofranil") and other psychotropic drugs in organic emotionalism. The British Journal of Psychiatry, 115(520), 281–285.CrossRefGoogle Scholar
  28. Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., … Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Medicine, 6(7), e1000100.CrossRefGoogle Scholar
  29. Lo, E. H., Singhal, A. B., Torchilin, V. P., & Abbott, N. J. (2001). Drug delivery to damaged brain. Brain Research. Brain Research Reviews, 38(1–2), 140–148.  https://doi.org/10.1016/S0165-0173(01)00083-2 CrossRefPubMedGoogle Scholar
  30. Miller, A., Pratt, H., & Schiffer, R. B. (2011). Pseudobulbar affect: The spectrum of clinical presentations, etiologies and treatments. Expert Review of Neurotherapeutics, 11(7), 1077–1088.  https://doi.org/10.1586/ern.11.68 CrossRefPubMedGoogle Scholar
  31. Moher, D. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264.  https://doi.org/10.7326/0003-4819-151-4-200908180-00135 CrossRefPubMedGoogle Scholar
  32. Moore, S. R., Gresham, L. S., Bromberg, M. B., Kasarkis, E. J., & Smith, R. A. (1997). A self report measure of affective lability. Journal of Neurology, Neurosurgery and Psychiatry, 63(1), 89–93.CrossRefGoogle Scholar
  33. Muller, U., Murai, T., Bauer-Wittmund, T., & von Cramon, D. Y. (1999). Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury, 13(10), 805–811.CrossRefGoogle Scholar
  34. Panitch, H. S., Thisted, R. A., Smith, R. A., Wynn, D. R., Wymer, J. P., Achiron, A., … Psuedobulbar Affect in Multiple Sclerosis Study Group. (2006). Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Annals of Neurology, 59(5), 780–787.  https://doi.org/10.1002/ana.20828 CrossRefPubMedGoogle Scholar
  35. Parizel, P., Özsarlak, Ö., Van Goethem, J., Van Den Hauwe, L., Dillen, C., Verlooy, J., et al. (1998). Imaging findings in diffuse axonal injury after closed head trauma. European Radiology, 8(6), 960–965.CrossRefGoogle Scholar
  36. Parvizi, J. (2001). Pathological laughter and crying: A link to the cerebellum. Brain, 124(9), 1708–1719.  https://doi.org/10.1093/brain/124.9.1708 CrossRefPubMedGoogle Scholar
  37. Parvizi, J., Arciniegas, D. B., Bernardini, G. L., Hoffmann, M. W., Mohr, J. P., Rapoport, M. J., … Tuhrim, S. (2006). Diagnosis and management of pathological laughter and crying. Mayo Clinic Proceedings, 81(11), 1482–1486.  https://doi.org/10.4065/81.11.1482 CrossRefPubMedGoogle Scholar
  38. Parvizi, J., Coburn, K. L., Shillcutt, S. D., Coffey, C. E., Lauterbach, E. C., & Mendez, M. F. (2009). Neuroanatomy of pathological laughing and crying: A report of the American neuropsychiatric association committee on research. Journal of Neuropsychiatry and Clinical Neurosciences, 21(1), 75–87.  https://doi.org/10.1176/appi.neuropsych.21.1.75 CrossRefPubMedGoogle Scholar
  39. Pattee, G. L., Wymer, J. P., Lomen-Hoerth, C., Appel, S. H., Formella, A. E., & Pope, L. E. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Current Medical Research and Opinion, 30(11), 2255–2265.  https://doi.org/10.1185/03007995.2014.940040 CrossRefPubMedPubMedCentralGoogle Scholar
  40. Pioro, E. P. (2011). Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs, 71(9), 1193–1207.  https://doi.org/10.2165/11591450-000000000-00000 CrossRefPubMedGoogle Scholar
  41. Pioro, E. P., Brooks, B. R., Cummings, J., Schiffer, R., Thisted, R. A., Wynn, D., … Efficacy Results Trial of AVP-923 in PBA Investigators. (2010). Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Annals of Neurology, 68(5), 693–702.  https://doi.org/10.1002/ana.22093 CrossRefPubMedGoogle Scholar
  42. Plantier, D., Luaute, J., & Group, S. (2016). Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice. Annals of Physical and Rehabilitation Medicine, 59(1), 42–57.  https://doi.org/10.1016/j.rehab.2015.10.003 CrossRefPubMedGoogle Scholar
  43. Presecki, P., & Mimica, N. (2007). Involuntary emotional expression disorder - new/old disease in psychiatry and neurology. Psychiatria Danubina, 19(3), 184–188.PubMedGoogle Scholar
  44. Rabins, P. V., & Arciniegas, D. B. (2007). Pathophysiology of involuntary emotional expression disorder. CNS Spectrums, 12(4 Suppl 5), 17–22.CrossRefGoogle Scholar
  45. Robinson, R. G., Parikh, R. M., Lipsey, J. R., Starkstein, S. E., & Price, T. R. (1993). Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry, 150(2), 286–293.  https://doi.org/10.1176/ajp.150.2.286 CrossRefPubMedGoogle Scholar
  46. Robinson-Smith, G., & Grill, J. D. (2007, 2007/08//). Recognizing involuntary emotional expression disorder. [disease/disorder overview]. Journal of Neuroscience Nursing, p. 202+.Google Scholar
  47. Rosen, H. (2008). Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today (Barc), 44(9), 661–668.  https://doi.org/10.1358/dot.2008.44.9.1258664 CrossRefGoogle Scholar
  48. Roy, D., McCann, U., Han, D., & Rao, V. (2015). Pathological laughter and crying and psychiatric comorbidity after traumatic brain injury. Journal of Neuropsychiatry and Clinical Neurosciences, 27(4), 299–303.  https://doi.org/10.1176/appi.neuropsych.15030045 CrossRefPubMedGoogle Scholar
  49. Rudolph, J. L., Fonda, J. R., Hunt, P. R., McGlinchey, R. E., Milberg, W. P., Reynolds, M. W., et al. (2016). Association of Pseudobulbar Affect symptoms with quality of life and healthcare costs in veterans with traumatic brain injury. Journal of Affective Disorders, 190, 150–155.  https://doi.org/10.1016/j.jad.2015.10.003 CrossRefPubMedGoogle Scholar
  50. Sauve, W. M. (2016). Recognizing and treating pseudobulbar affect. CNS Spectrums, 21(S1), 34–44.  https://doi.org/10.1017/S1092852916000791 CrossRefPubMedGoogle Scholar
  51. Schiffer, R., & Pope, L. E. (2005). Review of pseudobulbar affect including a novel and potential therapy. Journal of Neuropsychiatry and Clinical Neurosciences, 17(4), 447–454.  https://doi.org/10.1176/jnp.17.4.447 CrossRefPubMedGoogle Scholar
  52. Schoedel, K. A., Morrow, S. A., & Sellers, E. M. (2014). Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment, 10, 1161–1174.  https://doi.org/10.2147/NDT.S30713 CrossRefPubMedPubMedCentralGoogle Scholar
  53. Sloan, R., Brown, K., & Pentland, B. (1992). Fluoxetine as a treatment for emotional lability after brain injury. Brain Injury 6(4): 315–319Google Scholar
  54. Tateno, A., Jorge, R. E., & Robinson, R. G. (2004). Pathological laughing and crying following traumatic brain injury. Journal of Neuropsychiatry and Clinical Neurosciences, 16(4), 426–434.  https://doi.org/10.1176/jnp.16.4.426 CrossRefPubMedGoogle Scholar
  55. Team, N. D. R. (2010). Risk assessment and risk mitigation review - 021879Orig1s000. In D. o. H. a. H. services (Ed.): Food and Drug Administration; Centre for Drug Evaluation ResearchGoogle Scholar
  56. The Joanna Briggs Institute. (2014). Joanna Briggs institute reviewers’ manual (2014th ed.). Australia: The Joanna Briggs Institute.Google Scholar
  57. Traumatic Brain Injury Medical Treatment Guidelines (2012). In D. O. W. C. Department of Labor and Employment (Ed.). State of Colorado.Google Scholar
  58. Turner-Stokes, L., Hassan, N., Pierce, K., & Clegg, F. (2002). Managing depression in brain injury rehabilitation: The use of an integrated care pathway and preliminary report of response to sertraline. Clinical Rehabilitation, 16(3), 261–268.  https://doi.org/10.1191/0269215502cr489oa CrossRefPubMedGoogle Scholar
  59. Werling, L. L., Keller, A., Frank, J. G., & Nuwayhid, S. J. (2007). A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: Treatment of involuntary emotional expression disorder. Experimental Neurology, 207(2), 248–257.  https://doi.org/10.1016/j.expneurol.2007.06.013 CrossRefPubMedGoogle Scholar
  60. Willyerd, F. A., Empey, P. E., Kochanek, P. M., & Clark, R. S. (2014). Barriers to drug delivery for brain trauma. In Vascular Mechanisms in CNS Trauma (pp. 125-140): Springer.Google Scholar
  61. Work, S. S., Colamonico, J. A., Bradley, W. G., & Kaye, R. E. (2011). Pseudobulbar affect: An under-recognized and under-treated neurological disorder. Advances in Therapy, 28(7), 586–601.  https://doi.org/10.1007/s12325-011-0031-3 CrossRefPubMedGoogle Scholar
  62. Wortzel, H. S., Oster, T. J., Anderson, C. A., & Arciniegas, D. B. (2008). Pathological laughing and crying : Epidemiology, pathophysiology and treatment. CNS Drugs, 22(7), 531–545.CrossRefGoogle Scholar
  63. Yang, L. P. H., & Deeks, E. D. (2015). Dextromethorphan/quinidine: A review of its use in adults with Pseudobulbar affect. Drugs, 75(1), 83–90.  https://doi.org/10.1007/s40265-014-0328-z CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Monash-Epworth Rehabilitation Research Centre, Turner Institute for Brain and Mental Health, School of Psychological SciencesMonash UniversityMelbourneAustralia
  2. 2.Department of PsychiatryUniversity of MelbourneMelbourneAustralia
  3. 3.Department of Forensic MedicineMonash UniversitySouthbankAustralia
  4. 4.Albert Road Clinic, Department of PsychiatryUniversity of MelbourneMelbourneAustralia

Personalised recommendations